The Report
“Tresiba (Type 2 Diabetes) – Forecast and Market Analysis to 2022″ is
now available at MarketOptimizer.org. Contact sales@marketoptimizer.org with Report name in subject line and
your contact details to purchase this report or get your questions answered.
Researcher has
released its new report, “Tresiba (Type 2 Diabetes) Forecast and Market
Analysis to 2022″. The type 2 diabetes market is mature and crowded with
inexpensive generics. Despite being marked by a late-stage pipeline filled with
me-too drugs, this market will undergo substantial growth between 2012 and
2022, more than doubling over this period. The main drivers of growth will be
the dramatic increase in disease prevalence and physicians’ efforts to delay
disease progression and reduce the costly burden of diabetic complications
through the use of combination therapies and novel branded drugs.
Tresiba (insulin
degludec) is an ultra-long-acting basal insulin analog developed by Novo Nordisk
and launched in the EU in 2013. Tresiba is a modified insulin that has one
single amino acid deleted in comparison to human insulin, and is conjugated to
hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at
position B29.
Complete Report is available @ http://www.marketoptimizer.org/tresiba-type-2-diabetes-forecast-and-market-analysis-to-2022.html .
Scope
- Overview of type 2 diabetes,
including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tresiba
including product description, safety and efficacy profiles as well as a
SWOT analysis.
- Sales forecast for Tresiba for
the top ten countries from 2012 to 2022.
- Sales information covered for the
US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by
understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and
partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business
decisions from insightful and in-depth analysis of Tresiba performance
- Obtain sales forecast for Tresiba
from 2012-2022 in top ten countries (the US, France, Germany, Italy,
Spain, the UK, Japan, Brazil, India and China)
Buy the
copy of this Report @ http://www.marketoptimizer.org/contacts/purchase?rname=3439 .
Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes
18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and
Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile – Tresiba 29
Table 7: Tresiba SWOT Analysis, 2012 31
Table 8: Global Sales Forecasts ($) for Tresiba, 2012-2022 32
Table 9: Key Launch Dates 39
Table 10: Key Patent Expiries 39
Table 11: Number of High-Prescribing Physicians Surveyed 42
Inquiry
before buying this Report @ http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=3439 . (Single
User License : US$ 3495 And Corporate User License : US$ 10485)
For
further information on “Tresiba (Type 2 Diabetes) – Forecast and Market
Analysis to 2022” report Contact sales@marketoptimizer.org / Call +1 888 391 5441.
